What can we help you find?
A first-in-human trial evaluating the safety, pharmacokinetics, and fecal microbiome effects of a novel DNA polIIIC inhibitor demonstrated the antibacterial’s promise as a potential treatment alternative to vancomycin for the treatment of Clostridioides difficile.
The NFID released data that revealed only 52% of adults in the country plan to get vaccinated against the flu this season.
PharmSkills in Immunization: Opportunities for Retail and Health-System Pharmacists to Improve Adult Pneumococcal Immunization Rates
Continuing education to improving adult pneumococcal immunization rates.
Lefamulin (Xenleta, Nabriva Therapeutics) is the first IV and oral antibiotic with a novel mechanism of action approved by the FDA in nearly 2 decades, according to Nabriva.
A binational team of investigators at the University of California, Davis, has conducted the first comprehensive study to examine the risk factors for Rocky Mountain spotted fever in Mexicali, Mexico. They found that citywide, just 1 in 1000 ticks was infected with the disease, but in certain neighborhoods, about 1 in 10 ticks was infected.
Ceftolozane and tazobactam was initially approved by the FDA in 2014 o treat complicated intra-abdominal infections and for complicated urinary tract infections.
Brown Bagging is an essential educational and safety tool for helping treat community-acquired pneumonia.
The study presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands was a phase 2 randomized, active-controlled, double-blinded trial (N=444). All participants were ages 60 to 64 years.
A triad of techniques can reduce the likelihood of infection, and pharmacy teams can help patients with all of them.
The CDC has declared immunizations one of the greatest health achievements of the 20th century, but vaccination rates among adults remain suboptimal.
Officials with the FDA have approved Xellia Pharmaceuticals’ Premixed Vancomycin Injection in a Ready-to-Use (RTU) bag, according to the company.
HIV-positive patients with hepatocellular carcinoma had an adjusted 24% increased hazard of death compared to their HIV-negative peers.
+ Load More